不规则抗体筛查对临床输血的意义

目的:探讨不规则抗体的筛查在临床输血中的意义。方法:对2009年5月至10月间本院6300例输血患者做不规则抗体筛查,抗体筛检阳性者做进一步鉴定,分析抗体特异性,总结各抗体出现频率。结果:半年来检测病例6300例,检测出不规则抗体阳性9例,阳性率0.14%,其中抗-D抗体2例,抗-DC抗体1例、抗-E抗体2例,抗-e抗体1例,抗-M抗体3例。还检测出自身抗体3例及高度冷凝集1例。结论:不规则抗体筛选应作为输血前检查之常规,对保障临床用血、预防溶血性输血反应具有极其重要的意义。     

39302例患者不规则抗体筛查结果分析及其临床意义

目的:对需要输血的患者进行输血前不规则抗体筛查,为受血者选择合适的供血者血液成份,确保临床输血安全有效地进行。方法:选择2009年10月1日～2011年10月31日在本院入院进行治疗性输血和手术备血的患者,采用微柱凝胶法对受血者进行血清中不规则抗体的筛查,并对筛查阳性标本进抗体特异性鉴定。确保临床输血安全有效。结果:在39302例受血者血清中共检测出不规则抗体69例(阳性率0.18%),其中抗-D 5例、抗-E 15例、抗-C 2例、抗-c 2例、抗-e 2例、抗-C,e 1例、抗-M 8例、抗-S 1例、抗-Lea2例、抗-Leb1例、自身抗体5例、25例未确定抗体的特异性。结论:不规则抗体筛查对保证输血安全、降低免疫性溶血性输血反应、及时寻找相容血液及预防和减少新生儿溶血病的发生很有必要。     

RhD正定型及不规则抗体筛查的临床意义分析

目的:探究RhD正定型及不规则抗体筛查在预防临床输血不良反应中的应用价值及临床意义。方法:回顾性分析2010年至2011年、2017年至2018年于首都医科大学附属北京同仁医院输血科实施输血治疗的1892例患者,将2010年至2011年未实施Rh D正定型及不规则抗体筛查时输血治疗的901例患者设为对照组,将2017年至2018年实施RhD正定型及不规则抗体筛查后输血治疗的991例患者设为观察组。对比两组输血不良反应发生率,分析不同血液成分、不同性别、不同年龄输血不良反应发生率,并就2017年、2018年受血者RhD正定型及不规则抗体特异性分布进行罗列。结果:(1)2010年输血不良反应发生率为3.49%,2011年为2.40%,2017年为1.33%,2018年为0.74%,对照组不良反应发生率明显高于观察组(P<0.05)。(2)观察组不同血液成分输血的不良反应发生率显著低于对照组(P<0.05)。(3)两组不同年龄和性别输血不良反应发生率对比差异无统计学意义(P>0.05)。(4)观察组共检出20例RhD正定型及不规则抗体阳性患者,其中抗-M型5例,抗-D型3例,抗-E型2例,抗-C型2例,抗-P型2例,抗-LEa型1例,抗-LEb型1例,抗-JKa型1例,抗-N型1例,抗-H型1例,非特异性抗体1例。结论:RhD正定型及不规则抗体筛查能够显著降低输血不良反应发生率,有助于提高配血的准确性,提高输血治疗的安全性。     

不规则抗体筛查对临床安全输血的意义

目的:不规则抗体是血浆中除了抗A、抗B以外的其他血型抗体,会引起血型鉴定困难、疑难配血、溶血性输血反应及新生儿溶血症。本文探讨不规则抗体在住院患者中的发生情况,为需要输血的患者选择匹配的血液供应,确保临床输血安全、合理、有效。方法:利用Ⅰ~Ⅲ类谱细胞用微柱凝胶抗人球蛋白检测卡对住院患者血标本进行不规则抗体筛查,再对阳性标本利用Ⅰ~Ⅻ类谱细胞进行特异性鉴定。结果:13889例受检血标本中,检出不规则抗体25例,阳性率为0.18%。检出的不规则抗体涉及Rh、MNSs、Lewis、Kidd四个血型系统,所占比例分别为80%、8%、8%、4%。且不规则抗体在女性患者中的检出率高于男性患者。结论:输血前对患者进行不规则抗体筛查及特异性鉴定,可有效减少和避免溶血性输血反应的发生,对于安全输血是十分必要的。     

2623名患者红细胞不规则抗体筛选结果分析*

目的:对红细胞抗体筛选阳性的标本进行红细胞不规则抗体特异性鉴定与分析,为临床安全输血提供帮助。方法:2011年8月至2018年12月天津市各医院送至本中心实验室检测的2623份血液标本,进行红细胞不规则抗体筛选和鉴定;采用低离子强度溶液-抗人球蛋白微柱凝胶卡方法和盐水直接离心方法进行抗体筛选和抗体鉴定。结果:共检出2744个红细胞抗体,其中2139个为同种抗体,509个为自身抗体,96份标本未能确定抗体特异性;在所检出的同种抗体中,Rh系统的抗体最常见,占比为54.7％(其中抗-E 26.2％,抗-c 8.7％,抗-C 7.7％,抗-e 6.9％,抗-D 4.9％),MNS系统、Lewis系统、Kidd系统、P系统、Duffy系统、Kell系统、Diego系统均有抗体检出。结论:在输血前检测中,为预防检出不规则抗体的情况出现,应提前备血,以免由此导致的延迟输血,影响治疗。     

探索不规则抗体筛查与临床输血安全

输血是临床疾病治疗中非常普遍的医治手段,输血以输同型血、交叉配血为原则,若血型不匹配,则易引发溶血性输血反应,而不规则抗体的筛查可以有效地避免溶血性输血反应的发生,对于临床输血安全具有重要的意义。本文介绍了不规则抗体筛查的临床概念,分析了临床输血中存在的问题,以2010年10月至2014年5月期间在我院输血的患者共7826例为研究对象,分析了不规则抗体筛查的临床结果,并阐述了不规则抗体筛查在临床输血中的安全问题,从而探讨不规则抗体筛查与临床输血安全之间的关系,对于临床输血相关问题提供参考。     

Bioxun微柱凝胶筛查红细胞不规则抗体的研究

目的:探讨Bioxun微柱凝胶法(Bioxun Micro-column Gel anti-globulin Test,BMGT)筛查红细胞不规则抗体的敏感性和特异性。方法:使用盐水介质法(Saline Media Test,SMT)、传统抗人球法(Traditional anti-Globulin Test,TGT)、达亚美凝胶法(DiamedMicro-column Gel Test,DMGT)和Bioxun微柱凝胶法分别检测红细胞不规则抗体,对方法学灵敏度和特异性进行观察比较。结果:Bioxun微柱凝胶法与达亚美凝胶法的结果无显著差异(P>0.05),二者的敏感度和特异性超过盐水介质法和传统抗人球法(P<0.05)。结论:Bioxun微柱凝胶法操作快捷,敏感度高,适宜在临床输血中推广应用。     

自身抗体检测对 自身免疫性肝炎的临床诊断价值

目的通过对肝炎患者多种自身抗体检出率的比较,探讨其在自身免疫性肝炎中的临床诊断价值。方法对75例自身免疫性肝炎(AIH)患者,64例非AIH肝炎患者和78例健康体检者进行自身抗体检测。采用免疫印迹法检测抗线粒体抗体-M2(AMA-M2)、抗肝肾微粒体-1抗体(LKM-1)、抗肝细胞胞质抗原-1抗体(LC-1)、抗可溶性肝抗原/肝-胰抗原抗体(SLA/LP);采用间接免疫荧光法检测抗核抗体(ANA),并对各检测指标进行比对分析。结果AIH组患者ANA、AMA-M2、LKM-1、LC-1、SLA/LP检测阳性率分别为100.0%、28.0%、9.3%、1.3%、10.7%均高于非AIH组患者的56.2%、3.1%、0.0%、0.0%、0.0%,且除LC-1外其余差异均具有统计学意义(P0.05)。结论联合检测ANA、AMA-M2、LKM-1、LC-1及SLA/LP对诊断自身免疫性肝炎具有重要的临床意义。     

质粒DNA抗原芯片检测抗双链DNA抗体的初步研究

目的:建立以质粒DNA作为抗原的检测血清中抗双链DNA(dsDNA)抗体的芯片方法,并与酶联免疫吸附实验比较,初步探讨用芯片法检测抗dsDNA抗体的临床价值。方法:将原核表达载体质粒pcDNAⅡ用质粒DNA快速抽提试剂盒提取纯化DNA后按1∶2稀释,用点样仪点在经3-氨丙基三乙氧基硅烷(APES)修饰的玻片上,温孵后用含有1%小牛血清白蛋白和2.5%蔗糖的PBST封闭,以Cy3标记的人IgG为二抗,建立检测dsDNA抗体的芯片方法,并与德国欧蒙公司生产的抗双链DNA检测ELISA试剂盒做比较,对包括58例系统性红斑狼疮(SLE)、25例干燥综合征(SS)、10例皮肌炎(DM)和7例类风湿关节炎(RA)在内的病人和60例健康人对照进行了抗dsDNA的对比检测。结果:对阳性标本的检测,与现用常规检测方法ELISA相比,芯片检测抗dsDNA的灵敏度为91.3%,特异度为90.7%,阳性预测值为89.3%,阴性预测值为92.5%;对健康对照的检测,2种方法均为阴性,符合率为100%。结论:与ELISA相比,用质粒DNA作为抗原建立的芯片方法的灵敏度和特异度较高,为今后建立同时检测多个自身抗体的芯片奠定了基础。     

抗中性粒细胞胞浆抗体、抗核抗体联合检测对类风湿关节炎 的诊断价值

目的:探讨抗中性粒细胞胞浆抗体(ANCA)与抗核抗体(ANA)联合检测对类风湿关节炎的临床意义。方法:采用IIF法对82例RA患者(RA组)、74例非RA自身免疫疾病患者(非RA组)和52例健康体检者(正常对照组)的血清ANCA和ANA谱进行了检测分析,并用ELISA法进行抗丝氨酸蛋白酶3(PR3)、抗髓过氧化物酶(MPO)、ANA谱的定量检测。结果:RA组82例患者中,64例ANCA阳性,阳性率为78.08%,其中核周型(PANCA)37例,阳性率为45.1%,胞浆型(CANCA)27例,阳性率为32.9%;非RA组74例患者中有7例ANCA阳性率分别为9.4%;正常对照组50例中没有一例ANCA阳性。利用Elisa法对患者血清进行检测,分别能够特异的检测到PR3、MPO、抗双链DNA抗体(抗ds-DNA抗体)、抗ss-A等抗体、抗SS-A抗体、抗PM-SCL抗体的存在。结论:联合ANCA、ANA检测有助于提高类风湿关节炎的诊断。     

ABO血型正反定型及交叉配血实验在外科病人手术输血中应用

目的:探讨ABO血型正反定型及交叉配血实验在外科手术患者输血中的应用效果及影响因素。方法:选取我院自2017年2月-2019年2月收治的80例行ABO正反定型与交叉配血治疗的外科手术患者,记录ABO反定型与交叉配血不合的标本,使用2-Me处理被患者自身冷抗体凝集的红细胞,同时使用微柱凝胶法、凝聚胺法对血型不规则抗体以及特异性进行筛选和鉴定。分析ABO血型反定型不符合以及交叉配血不合的影响因素。结果:对正反定型完全无凝集反应的80例血清标本进行交叉配血实验,其中8例存在凝集反应,配血不合情况;导致外科手术患者输血中ABO血型反定型不符交叉配血不合的主要因素包括自身冷抗体、血型抗原性减弱、血型不规则抗体以及血型抗体效价减弱等。结论:ABO血型正反定型及交叉配血治疗中的患者中,大部分配血一致,少数的交叉配血不合,主要与自身冷抗体、血型抗原性减弱、血型不规则抗体以及血型抗体效价减弱等因素相关。     

Association of sex, age and ABO-Rh(D) type with unexpected antibodies among multitransfused thalassemia patients in Bikaner, Rajasthan, India

The thalassemia has become a sensitive issue for clinical and public health owing to the morbidity and mortality caused and potential risks associated with multiple transfusions. Here, a blood bank based cross sectional analytical study was carried out during the period of three months from January 2017 to March 2017, among transfusion dependent beta thalassemia major patients. ABO-Rh(D) blood grouping and screening for unexpected red cell antibodies (other than anti-A and anti-B antibodies) were performed on a Immucor Galileo Neo System (fully automated immunohematology analyzer). Out of 56 patients, 37 (66%) were males and 19 (34%) were females with a male to female ratio of 1.95:1. Two cases (3.6%) were detected positive by antibody screening. Alloimmunization was statistically analyzed on the basis of age, sex and subjects'' ABO-Rh blood group. This study underlines the need for unexpected antibody screening among thalassemic patients receiving blood transfusion therapy.     

Antibodies against HBV, HCV and HAV detected by using microparticle enzyme immunoassay in hepatitis outpatients

The presence of the hepatitis B surface antigen (HBsAg), of the antibodies against HBc, HCV and HAV was determined in outpatients in the period September 2005 - December 2006. The serum samples were analyzed by using Enzyme Immunoassay microparticles (Abbott AxSYM System). At least one test was positive in 238 patients (15.4%) of the total of 1547 patients. Of the 238 positive subjects, in 130 positive subjects (54.6%) the existence of HBV infection could be ascertained based on the presence of HBsAg or of the antibodies against HBc or of their association; 83 patients (34.9%) presented antibodies against HCV and in other 12 patients the antibodies against HCV were associated with HBsAg or with antibodies against HBc, suggesting the coexistence of HCV and HBV infection. The antibodies against HCV and the associations between HCV and HBV were mostly detected in subjects with the diagnosis of cirrhosis, liver failure or chronic hepatitis. Of the 13 (5.46%) patients with antibodies against HAV, 6 patients presented the associations: in 2 cases antibodies anti-HAV with positive HBsAg, in 1 case antibodies anti-HAV and anti-HBc with positive HBsAg, in 2 cases antibodies anti-HAV and anti-HBc and in 1 case antibodies anti-HAV and anti-HCV.     

自身抗体引起的ABO血型正反定型结果不一致

目的:对因自身抗体引起ABO血型正反定型结果不一致的疑难血标本进行血型鉴定和分析,探讨其原因和解决办法。方法:先用直接抗人球蛋白试验(DAT)和间接抗人球蛋白试验(IAT)确定ABO血型正反定型结果不一致的原因是由于自身抗体的存在,然后做吸收放散试验、抗体筛选试验等排除自身抗体的干扰以便血型的正确判定。结果:ABO血型正反定型结果不一致因自身抗体引起的有10例,其中温抗体7例,冷抗体3例,温抗体同时同种抗体阳性2例,冷抗体同时同种抗体阳性2例。结论:自身抗体会影响ABO血型的正确判定,选用合适的试验进行分析判断以提高血型鉴定的准确性。     

Dot-ELISA法检测血液及唾液HIV抗体的应用评价

评价人类免疫缺陷病毒1+2型抗体检测试剂盒(Dot-ELISA法)检测血清和唾液样本的临床性能。采用对照试验研究,选取背景清晰的研究对象200例,采集同一研究对象的血清和唾液样本,应用万泰生物药业公司生产的人类免疫缺陷病毒1+2型抗体检测试剂盒作为考核试剂,法国生物梅里埃公司生产的人类免疫缺陷病毒抗体诊断试剂盒(ELISA法)作为参考试剂,考核试剂检测结果与参考试剂及研究对象背景进行比较分析。考核试剂检测血清HIV抗体与参考试剂相比较,阳性符合率100%,阴性符合率100%,总符合率100%,Kappa值1.00,一致性为最强;考核试剂检测唾液HIV抗体与参考试剂检测结果相比较,阳性符合率98.78%,阴性符合率100%,总符合率99.50%,Kappa值0.99,一致性为最强。Dot-ELISA法人类免疫缺陷病毒1+2型抗体检测试剂盒对血清及唾液样本检测性能优越,适合HIV抗体快速筛查。     

Anti-pituitary antibodies in patients with hypopituitarism and their families: longitudinal observation.

In an attempt to investigate the clinical significance of anti-pituitary antibodies in patients with hypopituitarism, anti-pituitary antibody in plasma was examined in 10 such patients (7 cases of isolated ACTH deficiency, 1 of partial hypopituitarism, and 2 of Sheehan's syndrome), on two or three occasions with an interval of more than 6 months (longitudinal study). In a total of 16 relatives of these 4 patients (2 cases of Sheehan's syndrome, one in each of partial hypopituitarism and isolated ACTH deficiency) and one patient not involved in the longitudinal study, anti-pituitary antibodies were also examined (family study). Anti-pituitary antibodies reacting with rat pituitary cytoplasmic antigens (pituitary cell antibodies: PCA) and pituitary cell surface antibodies (PCSA) reacting with GH3 cells and/or AtT-20 cells were measured with indirect immunofluorescence. The longitudinal study revealed the disappearance of antibodies in 3 patients, 2 PCA positive and one both PCA and PCSA positive. In 3 patients, altered antibody titers or a newly appearing antibody were found during the follow-up period. In 4 patients, the pituitary antibodies were negative during the follow-up periods. Of 16 family members studied, positive PCA was found in 3 members (2 in the families of patients with PCA positive Sheehan's syndrome, and 1 in the family of the patients with PCA positive partial hypopituitarism). Positive PCSA was found in 4 members (one in each of families of patients with partial hypopituitarism and isolated ACTH deficiency and of two cases of Sheehan's syndrome), and weakly positive PCSA was found in one family member of a patients with PCA positive Sheehan's syndrome.(ABSTRACT TRUNCATED AT 250 WORDS)     

Epstein-Barr virus infection in the neonatal period and in childhood

In an attempt to detect and characterize congenital, neonatal and early childhood EBV infections, a prospective sero-epidemiological study was undertaken in 112 newborn infants and their mothers, 25 additional newborns undergoing exchange transfusion, 114 randomly selected hospitalized infants aged 0 to 3 years, and 109 siblings and parents of these infants. Leukocyte culture was attempted in all the newborns and in 25 pre- and post-transfusion.The findings of EBV seroconversion in six patients without clearly apparent illness, infectious mononucleosis in only one case with significant EBV antibody rise, seroreversion in three cases in early childhood, higher newborn than maternal EBV antibody titres in three cases and the establishment of two permanent lymphoblastoid cell lines from newborns following exchange transfusion raise the possibility of abortive primary EBV infection in early life. Congenital or neonatal infections following exchange transfusions, however, could not be substantiated with certainty since the EBV antibodies did not persist at follow-up except possibly in two cases. Parenteral transmission of the EB virus by exchange transfusion at birth is probably prevented by the presence of EBV antibodies in either donor or recipient.     

Comparison of NCL-hTERT antibody reactivity and telomere repeat amplification protocol in situ in effusions

OBJECTIVE: To compare the performances of 2 methods, telomerase repeat amplification protocol (TRAP) in situ and antibodies to the hTERT protein, in assessing telomerase activity. STUDY DESIGN: TRAP in situ and immunohistochemistry with a commercial antibody (NCL-hTERT) was performed on 54 body cavity effusions. The results were compared and correlated to diagnosis. RESULTS: Thirty-four effusions from patients with verified malignant disease contained cytologically malignant cells. Both methods were positive in 33 of the cases, whereas only hTERT was positive in 1 case. Twenty effusions, all containing mesothelial cells, came from patients with benign conditions. In 2 fluids atypical, hyperplastic mesothelial cells were both TRAP in situ and hTERT positive. All remaining 18 fluids were TRAP in situ negative, whereas 12 of 18 were hTERT positive. Thus the results of TRAP in situ and hTERT immunohistochemistry disagreed in 1 of 34 (3%) malignant and 12 of 20 (60%) benign cases. CONCLUSION: The sensitivities for malignancy were similar for TRAP in situ and hTERT immunohistochemistry. The specificity of the applied hTERT antibody was significantly lower, due to hTERT reactivity in mesothelial cells.